Department of Gastroenterology, Ajou University School of Medicine, Suwon, South Korea.
Clin Biochem. 2012 Jan;45(1-2):31-6. doi: 10.1016/j.clinbiochem.2011.09.023. Epub 2011 Oct 14.
The aims of this study were to determine the changes in serum histologic surrogate markers and to identify the serum markers predicting treatment response in patients with chronic hepatitis B (CHB) during entecavir treatment.
Sixty CHB patients who received entecavir for 12 months were included. We assessed serum markers of liver fibrosis and/or inflammation at baseline and after 12 months of entecavir treatment.
The procollagen III N-terminal peptide (PIIINP) and TIMP1, MMP2, hyaluronic acid and cytokeratin 18 fragment levels were significantly decreased and the haptoglobin level was significantly increased from baseline after entecavir treatment. Multivariate analysis identified PIIINP (P=0.028) and the initial virologic response (P=0.019) as independent predictors of HBeAg loss.
During entecavir treatment, most serum markers of liver fibrosis and inflammation improved in patients with CHB. The PIIINP level at baseline and the initial virologic response are independent predictors of HBeAg loss.
本研究旨在确定血清组织学替代标志物的变化，并确定接受恩替卡韦治疗的慢性乙型肝炎（CHB）患者治疗反应的血清标志物。
共纳入 60 例接受恩替卡韦治疗 12 个月的 CHB 患者。我们在基线和恩替卡韦治疗 12 个月时评估了肝纤维化和/或炎症的血清标志物。
恩替卡韦治疗后，脯氨酸 III 型前肽（PIIINP）和 TIMP1、MMP2、透明质酸和细胞角蛋白 18 片段水平显著降低，结合珠蛋白水平显著升高。多变量分析确定 PIIINP（P=0.028）和初始病毒学应答（P=0.019）是 HBeAg 丢失的独立预测因子。
在恩替卡韦治疗期间，CHB 患者的大多数肝纤维化和炎症的血清标志物得到改善。基线时的 PIIINP 水平和初始病毒学应答是 HBeAg 丢失的独立预测因子。
